This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GBIO Generation Bio (GBIO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Generation Bio Stock (NASDAQ:GBIO) Get Generation Bio alerts:Sign Up Key Stats Today's Range$5.34▼$5.3450-Day Range$5.34▼$5.7452-Week Range$3.00▼$6.95VolumeN/AAverage Volume160,744 shsMarket Capitalization$35.99 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingHold Company Overview Generation Bio, Inc. (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors. The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation. By combining optimized plasmid constructs with targeted lipid formulations, Generation Bio aims to achieve sustained, controlled levels of gene expression, potentially reducing the need for repeat dosing. Their pipeline includes early-stage programs in metabolic, neuromuscular, and ocular indications, where long-lasting therapeutic benefit is critical. Since its founding, Generation Bio has secured financing through private investments and completed a public offering to fund its research and development activities. The company collaborates with academic and industry partners to advance preclinical studies and to prepare for regulatory submissions. Its programs are primarily focused on patient populations in the United States and Europe, where it plans to conduct clinical trials and engage with regulatory authorities. Generation Bio is guided by a leadership team with extensive experience in biotechnology, gene therapy, and drug development. The management team includes scientists and executives who have previously held roles at leading biopharmaceutical companies and who bring expertise in translational research, clinical strategy, and regulatory affairs. As it progresses toward clinical milestones, Generation Bio aims to leverage its platform to deliver transformative treatments for patients with high unmet medical needs.AI Generated. May Contain Errors. Read More Generation Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreGBIO MarketRank™: 1.838 of 5 starsGeneration Bio scored higher than 37% of companies evaluated by MarketBeat, and ranked 698th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingGeneration Bio has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialGeneration Bio has a consensus price target of $8.50, representing about 59.2% upside from its current price of $5.34.Amount of Analyst CoverageGeneration Bio has received no research coverage in the past 90 days.Read more about Generation Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Generation Bio are expected to grow in the coming year, from ($1.75) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Generation Bio is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Generation Bio is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneration Bio has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GBIO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneration Bio does not currently pay a dividend.Dividend GrowthGeneration Bio does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for GBIO on MarketBeat in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Generation Bio insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.22% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Generation Bio's insider trading history. Receive GBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GBIO Stock News HeadlinesGeneration Bio (GBIO) Receives a Buy from WedbushJanuary 6, 2026 | theglobeandmail.comGeneration Bio (GBIO) price target decreased by 70.88% to 9.01December 21, 2025 | msn.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 23 at 1:00 AM | Altimetry (Ad)Jefferies downgrades Generation Bio (GBIO)December 18, 2025 | msn.comGeneration Bio price target lowered to $5.50 from $7 at WedbushDecember 16, 2025 | msn.comShareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public ShareholdersDecember 15, 2025 | prnewswire.comGBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to ShareholdersDecember 15, 2025 | businesswire.comXOMA Royalty Enters into Agreement to Acquire Generation BioDecember 15, 2025 | globenewswire.comSee More Headlines GBIO Stock Analysis - Frequently Asked Questions How were Generation Bio's earnings last quarter? Generation Bio Co. (NASDAQ:GBIO) issued its quarterly earnings results on Wednesday, November, 5th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($3.18) by $2.36. The business had revenue of $1.59 million for the quarter, compared to analyst estimates of $0.66 million. Generation Bio had a negative trailing twelve-month return on equity of 94.82% and a negative net margin of 410.13%. When did Generation Bio's stock split? Shares of Generation Bio reverse split on Tuesday, July 22nd 2025.The 1-10 reverse split was announced on Friday, July 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Generation Bio IPO? Generation Bio (GBIO) raised $200 million in an initial public offering on Friday, June 12th 2020. The company issued 10,526,316 shares at $19.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Generation Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Generation Bio investors own include Qualcomm (QCOM), NIO (NIO), Co-Diagnostics (CODX), FuelCell Energy (FCEL), Albertsons Companies (ACI), Alaska Air Group (ALK) and Salesforce (CRM). Company Calendar Last Earnings11/05/2025Today10/23/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GBIO CIK1733294 Webgenerationbio.com Phone617-655-7500FaxN/AEmployees150Year Founded2016Price Target and Rating Average Price Target for Generation Bio$8.50 High Price Target$15.00 Low Price Target$5.00 Potential Upside/Downside+59.2%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($9.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$131.67 million Net Margins-410.13% Pretax Margin-410.13% Return on Equity-94.82% Return on Assets-34.13% Debt Debt-to-Equity RatioN/A Current Ratio4.44 Quick Ratio4.44 Sales & Book Value Annual Sales$19.89 million Price / Sales1.81 Cash FlowN/A Price / Cash FlowN/A Book Value$12.91 per share Price / Book0.41Miscellaneous Outstanding Shares6,740,000Free Float5,316,000Market Cap$35.99 million OptionableOptionable Beta2.05 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:GBIO) was last updated on 2/9/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Generation Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
